This study focuses on patients who have an advanced cancer that has not responded to treatment with other therapies. The purpose of the study is to evaluate the safety of an investigational drug called ASTX029 and to find the appropriate dose to use in future studies, particularly in tumors with specific mutations. Participants will receive increasing doses of the study drug to find the highest dose that can be safely given and that also produces the expected effects on tumor cells. After the best dose and regimen is determined, participants with specific types of tumors that may be more sensitive to ASTX029 will receive the drug at selected doses and regimens.
What is the full name of this clinical trial?
ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Andrew Hendifar, Bobbie Jo Rimel, Edwin Posadas, Jun Gong, Karen Reckamp, Kevin Scher, Monica Mita, Omid Hamid, Robert Figlin, Ronald Natale